Alpha adrenoceptor sites in vascular smooth muscle. Differentiation by selective antagonist binding

Assessing the agonist profiles of the prostacyclin analogues treprostinil and naxaprostene, particularly their DP₁ activity

In this study, the inhibitory profiles of the prostacyclin analogues treprostinil and naxaprostene on several isolated smooth muscle preparations have been investigated. Treprostinil was an agonist for prostanoid DP1, EP2 and IP receptors, but not EP4 receptors; its DP1 potency was only 3-4 times less than PGD2 itself. Naxaprostene was much more selective for IP receptors and tended towards partial agonism. Treprostinil is a 13,14-dihydro analogue and the role of conformation around C12-15 in controlling agonist specificity is debated; the synthesis of new analogues is proposed and possible clinical usage discussed. In terms of selective prostanoid antagonists employed, BW-A868C/MK-0524 (DP1), ACA-23 (EP2) and GW-627368 (EP4) were found fit for purpose. However, the IP antagonist RO-1138452 was compromised by α1 and α2-adrenoceptor-mediated contractile activity on rat tail artery and anti-muscarinic activity on mouse trachea. There is a need for IP receptor antagonists with better selectivity and higher affinity.

Centrally Acting Imidazolines Stimulate Vascular Alpha 1A-Adrenergic Receptors in Rat-Tail Artery

: 1. Centrally acting imidazoline antihypertensive agents clonidine and moxonidine also act peripherally to contract blood vessels. While these agents act at both I(1)-imidazoline and alpha 2 adrenergic receptors centrally, the receptor types by which they mediate contraction require further definition. We therefore characterized the receptor subtype by which these agents mediate contraction of proximal rat-tail artery. 2. Dose-response curves were determined for phenylephrine and for several imidazoline ligands, using endothelium denuded, isolated ring segments, of tail arteries from adult male Sprague-Dawley rats. Ring segments were mounted on a force transducer with platinum wires and immersed in a tissue bath containing Krebs solution, to which drugs could be added. Signals were digitized and recorded by a computer. 3. Tail artery contractions expressed as a percent of contraction to 106 mM potassium were phenylephrine (96%), moxonidine (88%), clonidine (52%), and UK14304 (30%). Neither rilmenidine nor harmane caused contraction. Contraction of tail artery to moxonidine or clonidine could be blocked by alpha 1 antagonist urapidil or prazosin, and also by alpha 1A subtype selective antagonist WB4101. Schild plots were generated and a calculated pA2 value of 9.2 for prazosin in the presence of clonidine confirms clonidine as an agonist at alpha 1A receptors in proximal segments of rat-tail artery. 4. Our work suggests that clonidine and moxonidine are promiscuous compounds at micromolar concentrations and that harmane and rilmenidine are more selective compounds for in vivo imidazoline research.

A quantitative description of the contraction of blood vessels following the release of noradrenaline from sympathetic varicosities

A model is presented that highlights the principal factors determining the form and extent of contraction in arteries upon stimulation of their sympathetic nerve supply. This model incorporates a previous quantitative model of the process of noradrenaline (NAd) diffusion into the vascular media and reuptake into sympathetic varicosities during nerve stimulation (J. Theor. Biol. 226 (2004) 359). It is also dependent on a model of how the subsequent activation of metabotropic receptors initiates a G-protein cascade, resulting in the production of inositol trisphosphate (IP3) and an increase in intracellular calcium concentration, [Ca2+]i, in the smooth muscle cells (J. Theor. Biol. 223 (2003) 93). In the present work we couple this rise in [Ca2+]i to the increase in phosphorylated myosin bound to actin in the cells and hence determine the force development in arteries due to nerve stimulation. The model accounts for force development as a function of [Ca2+]i and for the rate of change of force as a function of the rate of change of [Ca2+]i in single smooth muscle cells. It also accounts for the characteristic time course of the force developed by the media of the rat-tail artery upon nerve stimulation. This consists of a rapid rise to a transient peak followed by a sustained plateau of contraction during the stimulation period, after which the contraction slowly decays back to baseline at a rate dependent on the strength of the stimulation. The model indicates that the transient peak is primarily due to the partial block of the IP3 receptor by the rise in [Ca2+]i and that the main determinant of the equilibrium condition indicated by the plateau phase is the rate of pumping of calcium into the sarcoplasmic reticulum. The relatively slow decline of contraction at the end of nerve stimulation is primarily a consequence of the slow rates of removal of NAd from the media by diffusion and reuptake into the sympathetic varicosities. The model thus provides a quantitative account of vascular smooth muscle contraction upon sympathetic nerve stimulation.

Moxonidine, an Antihypertensive Agent, is Permissive to α1-Adrenergic Receptor Pathway in the Rat-Tail Artery

To investigate whether alpha1-adrenergic receptors were involved in the contractile response of tail arteries to moxonidine, isolated ring segments of tail arteries from male adult Sprague-Dawley rats were studied. Moxonidine (EC50 = 1.3 microM) and the alpha1-agonist phenylephrine (EC50 = 2.5 microM) increased tension development in the rat-tail artery similarly. The response to moxonidine (1 microM) could be blocked by both alpha1-adrenoceptor blockers prazosin (IC50 = 1 nM), and urapidil (IC50 = 14 nM), and also by alpha2-adrenoceptor blockers, yohimbine (IC50 = 49 nM) and efaroxan (IC50 = 49 nM). Combination drug treatment (urapidil and yohimbine, or yohimbine and prazosin) was more effective in blocking the contractile response to moxonidine, than treatment with prazosin or urapidil alone. Comparison of pA2 values for prazosin in the presence of moxonidine (9.35) or phenylephrine (10.2) confirm that alpha1-adrenergic receptors are involved in the contractile response of rat-tail artery to moxonidine.

Noradrenaline stimulation of high-affinity GTPase activity in membranes from rat aorta and caudal artery

The ability of noradrenaline (NA) to stimulate increases in high-affinity GTPase activity in sarcolemma-enriched rat aorta and caudal artery membranes was examined in the present study. In aortic membranes, NA significantly (P < 0.05; N = 5) increased the Vmax from a basal value of 103 +/- 29 to 156 +/- 38 pmol Pi/min/mg protein, but did not affect the Km which was 0.32 +/- 0.08 microM in the absence and 0.58 +/- 0.16 microM in the presence of NA. However, in caudal artery membranes, NA significantly (P < 0.05; N = 6) increased both the Vmax and the Km from basal values of 69 +/- 12 pmol Pi/min/mg protein and 0.24 +/- 0.05 microM, respectively, to 205 +/- 54 pmol Pi/min/mg protein and 1.01 +/- 0.25 microM, respectively. Removing the endothelium from both artery preparations did not alter significantly basal GTPase activity or the magnitude of the increase stimulated by NA. Prazosin significantly inhibited NA-stimulated increases in GTPase activity in membranes from endothelium-denuded caudal artery and aorta, and in endothelium-intact caudal artery membranes. However, yohimbine significantly inhibited NA-stimulated increases in GTPase activity only in preparations from endothelium-intact caudal arteries. Therefore, in endothelium-intact caudal artery membranes, NA stimulated increases in GTPase activity that were apparently mediated by both alpha 1-adrenoceptors and alpha 2-adrenoceptors, while in endothelium-denuded aortic and caudal artery membranes this increase was mediated solely by alpha 1-adrenoceptors. Western blotting of these arteries confirmed the presence of both Gi alpha 2,3 and Gq/11 alpha, which are candidates for mediating the alpha 1-adrenoceptor-stimulated increases in GTPase activity.

Choline+ is a low-affinity ligand for alpha 1-adrenoceptors

The effect of choline+, a commonly used Na+ substitute, on ligand binding to alpha 1-adrenoceptors was investigated. It was found that replacement of 25% of the Na+ in a Krebs-Ringer bicarbonate buffer with choline+ led to a 3-fold decrease in the apparent affinity of [3H]prazosin for its binding site (i.e. the alpha 1-receptor) in a membrane preparation from brown adipose tissue, while no decrease in the total number of binding sites was observed. Similar effects were seen in membrane preparations from liver and brain. In competition experiments, it was found that choline+ could inhibit [3H]prazosin binding; from the inhibition curve, an affinity (Ki) of 31 mM choline+ for the [3H]prazosin-binding site could be calculated. In fully choline(+)-substituted buffers, where the level of [3H]prazosin binding was substantially reduced, both phentolamine and norepinephrine could still compete with [3H]prazosin for its binding site, with virtually unaltered affinity; thus choline+ did not substantially affect the characteristics of those receptors to which it did not bind. Choline+ did not affect the binding characteristics of the beta 1/beta 2 radioligand [3H]CGP-12177; thus, the effect on alpha 1-receptors was not due to general, unspecific effects on the membrane preparations. It is concluded that choline+ possesses characteristics similar to those of a competitive ligand for the alpha 1-adrenoceptor; it has a low affinity but the competitive type of interaction of choline may nonetheless under experimental conditions interfere with agonist interaction with the alpha 1-receptor.

The effects of alpha-adrenoceptor agonists on intracellular Ca2+ levels in freshly dispersed single smooth muscle cells from rat tail artery

1. The presence of functional alpha-adrenoceptors in freshly dispersed single smooth muscle cells from rat tail arteries was investigated by use of selective alpha-adrenoceptor agonists and antagonists. 2. Cirazoline, a selective alpha 1-adrenoceptor agonist, caused a prazosin-sensitive, rapid but transient increase in intracellular Ca2+, which was partially inhibited by the voltage-dependent Ca2+ channel blocker, nifedipine. 3. TL99, an alpha 2-adrenoceptor agonist, in the presence of prazosin, initiated a slow and sustained increase in intracellular Ca2+ which was partially inhibited by yohimbine and almost completely blocked by nifedipine. 4. In rat tail artery, the effects (dose-response and time-response curves) of cirazoline and TL99 on intracellular Ca2+ levels in freshly dispersed single smooth muscle cells were comparable with those obtained with organ bath studies of ring preparations of artery. 5. In freshly dispersed single smooth muscle cells, the time-course response curves induced by the selective alpha 1-adrenoceptor agonist, phenylephrine and the selective alpha 2-adrenoceptor agonist, UK14304, were similar to those observed with cirazoline and TL99, respectively. 6. These results indicate that: (a) functional alpha 1- and alpha 2-adrenoceptors are present in freshly dispersed single smooth muscle cells from rat tail artery and (b) alpha 1- and alpha 2-adrenoceptors are coupled to different cellular processes that lead to an increase in intracellular Ca2+.

Alpha-adrenoceptor activation of polyphosphoinositide hydrolysis in the rat tail artery

alpha-Adrenoceptor coupling to polyphosphoinositide (PI) hydrolysis was studied in the rat tail artery. Inositol phosphate (IP) accumulation was stimulated by the non-selective alpha-adrenoceptor agonist norepinephrine and the alpha 1-adrenoceptor agonist phenylephrine. This stimulation was relatively dependent on extracellular Ca2+ and enhanced markedly in the presence of LiCl. In addition, norepinephrine- and phenylephrine-stimulated IP accumulation was relatively sensitive to blockade by prazosin, compared to rauwolscine. The putative alpha 2-adrenoceptor agonist UK 14304 also stimulated PI breakdown in a concentration-dependent manner, although this stimulation did not reach equilibrium at up to 10 mM and was relatively sensitive to prazosin, compared to rauwolscine, over the lower agonist concentrations. NaF stimulated IP accumulation independently of alpha-adrenoceptor activation. PI breakdown by alpha-adrenoceptor agonists and NaF was attenuated by N-ethylmaleimide but not pertussis toxin treatment. In addition, dithiothreitol blocked NaF-stimulated, but not alpha-adrenoceptor-mediated. PI breakdown. These results suggest the coupling of alpha 1-adrenoceptor, via phospholipase C, to PI hydrolysis in the rat tail artery. This study also provides evidence for the involvement of one or more non-Gi-like G-protein(s) in the signal transduction process.